- Home
- ARWR vs AXSM Comparison
ARWR vs AXSM Comparison
Compare ARWR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | AXSM |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.0B |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARWR | AXSM |
|---|---|---|
| Price | $55.13 | $156.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $81.50 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 1.9M | 493.1K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | 38.56 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $16,142,321.00 | N/A |
| Revenue This Year | N/A | $58.34 |
| Revenue Next Year | N/A | $54.30 |
| P/E Ratio | $249.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.66 | $86.99 |
| 52 Week High | $76.76 | $191.50 |
Technical Indicators
Market Signals| Indicator | ARWR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 31.90 |
| Support Level | $36.34 | $148.14 |
| Resistance Level | $66.37 | $191.13 |
| Average True Range (ATR) | 3.12 | 4.67 |
| MACD | -0.84 | -1.37 |
| Stochastic Oscillator | 8.07 | 9.19 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.